Clinical Trial Update: A Retrospective Study of Safety and Efficacy of Locoregional Therapies Combined With Anti-VEGF/TKIs and Immune Checkpoint Inhibitors for All Comers of Intention-to-treat Patients With Unresectable Hepatocellular Carcinoma

View source ↗

Summary

A retrospective analysis evaluating safety and efficacy of combining locoregional therapies with anti-VEGF/TKIs and immune checkpoint inhibitors in patients wit…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Drugs mentioned

• Multiple therapies (locoregional therapies plus anti-VEGF/TKIs and immune checkpoint inhibitors)

Snippet

Sponsor: Ningbo Medical Center Lihuili Hospital | Conditions: Hepatocellular Carcinoma, Hepatocellular Carcinoma Non-resectable | Status: NOT_YET_RECRUITING